- Home
- DCOM vs AGIO Comparison
DCOM vs AGIO Comparison
Compare DCOM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | AGIO |
|---|---|---|
| Founded | 1864 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DCOM | AGIO |
|---|---|---|
| Price | $38.61 | $34.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $46.00 | $46.00 |
| AVG Volume (30 Days) | 298.5K | ★ 947.3K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 329.09 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | $19,907,000.00 | ★ $43,011,000.00 |
| Revenue This Year | $14.41 | $229.47 |
| Revenue Next Year | $10.39 | $94.99 |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.63 | $22.24 |
| 52 Week High | $41.97 | $46.00 |
Technical Indicators
Market Signals| Indicator | DCOM | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 57.81 |
| Support Level | $38.38 | $32.17 |
| Resistance Level | $41.45 | $35.77 |
| Average True Range (ATR) | 0.68 | 1.22 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 42.18 | 98.32 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.